Kornimate/medical-research-clean huggingface dataset:
i-sleep: internet-based treatment for insomnia

Conditions: Insomnia

Summary: in this study, people who suffer from insomnia will be randomized to one of three study conditions. the first group receives a multicomponent internet-based cognitive behavioral self-help intervention. the second group has access to an internet-based self-help sleep restriction intervention. the third group is a waiting control group. in both active conditions additional care or treatment is allowed. the aim of the study is to investigate the effectiveness of a multicomponent internet-based cognitive behavioral self-help intervention as well as a stand-alone internet-based self-help sleep restriction intervention for insomnia symptoms compared to a waiting list. assessments take place at baseline, and 8-weeks and 6-months post-randomization. after 8 weeks, participants in the waiting control group get access to the internet-based cognitive behavioural self-help intervention and also fill out questionnaires at 6-months post-randomization.


Eligibility criteria:
inclusion criteria: * being 18 years of age or older * meet icsd-3 diagnostic criteria for insomnia as confirmed by the telephone administered interview * acess to the internet * written informed consent exclusion criteria: * physiological insomnia * serious psychiatric co-morbidity that requires alternative treatment including major depression disorder, anxiety disorder, substance dependence, bipolar affective disorder, psychotic illness * epilepsy (seizure disorder)
secondary mentoring program evaluation

Conditions: Satisfaction

Summary: mentorship is essential to job satisfaction and promotion among academic physicians, and literature suggests that a single mentor is rarely sufficient. the investigators are studying whether implementation of a secondary mentorship program among physicians at their institution leads to improved job satisfaction over 6 months.


Eligibility criteria:
inclusion criteria: physician employed as full-time faculty in the massachusetts general hospital department of medicine. exclusion criteria: none
medications effect on lenstar measurements

Conditions: Cataract

Summary: prior to cataract surgery the lens must be calculated to appropriately fit a patient for the intraocular lens implant. lenstar is an optical biometer that calculates the axial length, keratometry, lens thickness, pupillometry, and anterior chamber depth. dilation drops are routinely used in eye exams in addition to pre-cataract surgery. the dilation drops include tropicamide 1%, and phenylephrine 2.5%. the tropicamide achieves the dilation of the pupil which causes an anterior rotation of the ciliary body, which may affect the lenstar measurements. this study is to determine if dilating medications affect the lens power prediction for emmetropia by the lenstar biometer. prior to dilation, lenstar biometry will be performed on each eye. patients will receive dilation medication and after waiting 20 minutes lenstar biometry will be performed on each eye. dilation and measurement with lenstar will be done as standard of care. measurements and calculations from before and after will be compared.


Eligibility criteria:
inclusion criteria: * candidates for cataract surgery undergoing routine evaluation of cataracts. exclusion criteria: * patients that have had their cataracts removed * patients that cannot undergo routine evaluation for cataract surgery (because they are too ill to sit upright in a chair)

Keywords: dilation intraocular ophthalmology
heart failure in norway: clinical characteristics, mortality and health care resource use

Conditions: Heart Failure; Heart Failure With Preserved Ejection Fraction; Heart Failure With Reduced Ejection Fraction

Summary: the prevalence of heart failure above 70 years of age is 10% and 5 year mortality rate above 60%, higher than for cancer. the readmission rate first after hospitalisation is 44% despite the availability of life prolonging and life quality enhancing treatment. there is a lack of resources for adequate diagnostic workup necessary for implementing evidence-based treatment. this projects aims at assessing the impact of guidelines based diagnostic workup and guidelines based treatment of heart failure on mortality and readmission rates. as the symptoms defining the degree of heart failure and the discharge medication only is available in the electronic patient files, artificial intelligence is used to retrieve this information to assess if treatment is according to guidelines. the project is using first a rule based text processing approach using ibm watson, then advancing to a machine learning approach using readmission and mortality as endpoints. the project has access to digitally stored echocardiographic measurements as well as digital ecg's and lab data on 15 000 patients admitted with a diagnosis of heart failure. if the retrieval of symptoms and function by artificial intelligence is successful, the next step is to assess if those benefitting the most from echocardiography can be identified using information from the ecg's, lab data or symptoms and functional capacity as described in the electronic health records.


Eligibility criteria:
inclusion criteria: diagnosis with icd10 codes as follows; i50.\*, i42.3, i11.\* and copd j44.\* from 2007 through 2019. in addition all subjects with nt-probnp above age specific normal range in same period. exclusion criteria: none
tace combined with immune checkpoint inhibitors for liver malignant tumors

Conditions: Hepatocellular Carcinoma Non-resectable; Cholangiocarcinoma Non-resectable; Liver Metastases; Liver Malignant Tumors

Summary: this study will evaluate the efficacy and safety of tace combined with immune checkpoint inhibitors to treat unresectable hepatocellular carcinoma.

the specific operation of tace is based on the csco diagnosis and treatment guidelines for primary liver cancer (2022 edition). tace is performed through microcatheters. after tace, the coaxial catheter is retained in the hepatic artery or left or right hepatic artery branch. the specific body plan is oxaliplatin+calcium folinate+5-fu (folfox) (j hepatol, 2018). oxaliplatin 85mg/m2 was continuously injected through arterial pump for more than 4 hours on the first day. after haic is completed, remove the catheter and sheath. repeat catheterization in the next treatment cycle. immune checkpoint inhibitors can be administered arterial starting after the first tace treatment, q4w (± 3 days). if the situation requires, the arterial administration of ici can be adjusted forward or backward for 7 days to adapt to tace treatment.

Eligibility criteria:
inclusion criteria: * confirmed diagnosis of hcc by histology/ cytology or clinical criteria * sign informed consent * when screening for age, the age should be ≥ 18 years old * eligible for tace treatment * ecog physical condition score is 0 or 1 * no prior systemic therapy for hcc, especially immunotherapy * according to the following mrecist criteria, at least one measurable intrahepatic lesion is suitable for repeated evaluation exclusion criteria: * have any history of kidney disease or nephrotic syndrome * evidence of extrahepatic spread (ehs) * cardiovascular diseases with clinical significance (such as activity), including unstable angina, ≥ grade 2 congestive heart failure, and arrhythmia with poor drug treatment control * any condition representing a contraindication to tace as determined by the investigators * known genetic factors for bleeding or thrombosis; any previous or current evidence indicating a tendency for bleeding * individuals who have received immunotherapy (anti pd-1, anti pd-l1, or anti ctla-4 treatment) * previously received haic (hepatic artery infusion chemotherapy), tace (hepatic artery chemoembolization), tae (hepatic artery embolization), or tare (hepatic artery radiation embolization) * previously received systemic anti-cancer treatment for hcc ,icc or liver metastasis.

Keywords: hepatocellular carcinoma cholangiocarcinoma liver metastases liver malignant tumors
apical external root resorption secondary to orthodontic forces and individual radicular stress

Conditions: Apical Root Resorption

Summary: the goal of this prospective clinical trial is to evaluate the possible superiority of a treatment compared to the gold standard of reference in orthodontics.

apical external root resorption is defined as the loss of dental hard tissues such as dentine, cement and alveolar bone. this is considered an irrevocable effect associated to different factors, among which dental movement during orthodontic treatment is related. this study suggest to compare root resorption after the use of two different types of alignment and levelling arches in orthodontics. consecutive patients randomly chosen will be analysed after going through one of the two arches sequences: 1. gold standard group: using arches that provide the same amount of force in all sections . 3m united® nickel-titanium arches (0.012, 0.014, 0.016 x 0.016, 0.020 x 0.020, 0.018 x 0.025 y 0.019 x 0.025) 2. intervention group: using some arches that provide individual sectional forces for each dental group (incisors, premolars and molars). 3m united® nickel-titanium 0.012 and 0.014 arches and bioforce plus® arches (0.016 x 0.016, 0.020 x 0.020, 0.018 x 0.025 y 0.019 x 0.025). all patients will be treated with multi-braces fixed appliances (0.022" technique and victorytm brackets). root resorption will be compared through cbct (cone beam computed tomography) images made before the beginning of treatment (t0), after 8-9 months of the beginning of treatment (t1) and at the end of treatment (t2). root resorption will be measured by the root volume and surface root morphology in each of the times scheduled.

Eligibility criteria:
study population: patients undergoing orthodontic treatment in orthodontic department at dental school of universidad complutense de madrid. inclusion criteria: 1. completed permanent dentition (third molars are excluded) 2. completed root formation 3. need of orthodontic treatment exclusion criteria: 1. tooth agenesis in the anterior region (incisors) 2. included or ankylosed teeth in the anterior region (incisors) 3. periodontal pocket \>3 mm in any anterior teeth (incisors) 4. need of a combined surgical and orthodontic treatment 5. root resorptions observed at the initial cbct (in more than 3 teeth) 6. delay of the treatment due to a external reason or complication during treatment 7. systemic disease or cranio-facial malformation 8. tooth fracture or restoration in the anterior region (incisors) at the beginning of treatment 9. problems from roots such as lacerated root, trauma or fractures during treatment 10 severe occlusal attrition
efficiency of abdominal corset and core stabilization exercises in the treatment of postpartum diastasis recti abdominis

Conditions: Diastasis Recti

Summary: participants will be randomly divided into three groups as core stabilization group, combination of core stabilization and corset group and only corset group.

30 volunteer women who were diagnosed with diastasis recti abdominis by an obstetrician in çamlıca medipol hospital, aged between 18-35 and met the inclusion criteria will be included in the study. participants will be randomly divided into three groups. participants in the first group will do core stabilization exercises for the transversus abdominis muscle 3 days a week for 8 weeks with 10 repetitions. in the second group, in addition to the first group, core stabilization exercises will be performed by wearing an abdominal corset. participants included in the third group will be asked to wear only this corset all day (except for the bathroom) for 8 weeks. anthropometric measurements, ultrasonographic evaluation, visual analogue scale (vas), edinburgh postnatal depression scale, abdominal muscle strength and endurance, oswestry disability index will be evaluated as pretest and posttest.

Eligibility criteria:
inclusion criteria: * being between the ages of 20-35, * having a normal birth, * being at least 6 weeks postpartum when dra is diagnosed, * absence of any musculoskeletal or neurological problems, * volunteering to do the exercises exclusion criteria: * cesarean delivery, * edinburgh postnatal depression questionnaire result being \>13, * having a systemic disorder

Keywords: diastasis recti abdominis core stabilization exercise physiotherapy
blood coagulation abnormalities in covid-19 (corona virus disease-19) patients

Conditions: Covid19

Summary: the role of the coagulation parameters in predicting the severity of covid-19 disease will be assessed

in covid-19 patients the coagulation parameters prothrombin concentration (pc), activated partial thromboplastin time (aptt), d dimer, antithrombin iii (atiii) and fibrinogen are measured and correlation with disease severity is to be investigated

Eligibility criteria:
inclusion criteria: ● confirmed cases with covid 19 exclusion criteria: ● known history of blood coagulopathy disorder
simvastatin effect on end stage renal failure patients treated by peritoneal dialysis

Conditions: Renal Failure, End Stage; Peritoneal Dialysis

Summary: this study will analyse the effect of simvastatin on endothelium dependent venodilation in chronic renal failure patients treated by peritoneal dialysis. the hypothesis is that patients will have a greater endothelium dependent venodilation after four months of simvastatin use.

this study will analyse the effect of simvastatin on endothelium dependent venodilation in chronic renal failure patients treated by peritoneal dialysis. the hypothesis is that patients will have a greater endothelium dependent venodilation after four months of simvastatin use.

Eligibility criteria:
inclusion criteria: * end stage renal failure * peritoneal dialysis * ldl cholesterol \> 100mg/dl * \> 18 years and \< 80 years exclusion criteria: * using statin or nitrate * liver disease * diabetes mellitus

Keywords: end stage renal failure peritoneal dialysis simvastatin endothelium vasodilation
dopamine d2 receptors(d2r) imaging in nonfunctioning pituitary adenoma(nfpa)

Conditions: Pituitary Adenoma

Summary: to study the in vivo expression of dopamine d2 receptors in nonfunctioning pituitary adenoma and the predictive role of dopamine dopamine d2 receptors pet-mr imaging in the therapeutic effect of dopamine agonists（da）.

dopamine agonists are the first line therapy for prolactinoma,which are also effective in some cases of other subtypes of pituitary tumors. it had been showed that dopamine agonists inhibit prolactin secretion by binding to and activating dopamine d2 receptors. pet-mr combined mr images with pet function images is substantial to evaluate the expression of dopamine d2 receptors.the aim is to study the in vivo expression of dopamine d2 receptors in prolactinoma and the predictive role of dopamine d2 receptors pet-mr imaging in the therapeutic effect of dopamine agonists.

Eligibility criteria:
inclusion criteria: 1. normal serum pituitary hormone levels or mild increase of serum prolactin. 2. enhanced mri shows a pituitary tumor and tumor diameter\>1cm. 3. aged between 18 and 65 years old, either sex. 4. karnofsky performance status ≥ 70. 5. the patient has signed the informed consent. exclusion criteria: 1. patients concomitantly taking the psychotropic drugs. 2. patients with parkinson disease and is taking dopaminergic agents. 3. patients with pituitary adenoma who received gamma knife treatment. 4. pregnant or lactating women. 5. patients with poor compliance, who cannot implement the program strictly. 6. history of allergic reactions attributed to compounds of similar chemical or biologic composition to cabergoline. 7. patients with claustrophobia. -

Keywords: nonfunctioning pituitary adenoma dopamine agonist dopamine d2 receptors pet-mr
comparison of ketamine-propofol combinations

Conditions: Agitation; Postoperative Pain

Summary: asa i-ii 3-12 years old children participated to this study. all participants will divide into the three groups. in groups i, 2,5 mg/kg propofol and 0,5 mg/kg ketamine will apply at anaesthesia induction. general anaesthesia will be performed with 5/1 ratio of ketamine-propofol mixture with %67 of mcfarlan dose regiment. in groups ii, 2,75 mg/kg propofol and 0,41 mg/kg ketamine will apply at anaesthesia induction. general anaesthesia will be performed with 6,7/1 ratio of ketamine-propofol mixture with %80 of mcfarlan dose regiment. in groups iii, 3 mg/kg propofol and 0,3 mg/kg ketamine will apply at anaesthesia induction. general anaesthesia will be performed with 10/1 ratio of ketamine-propofol mixture with %90 of mcfarlan dose regiment. after than surgical operation recovery time, paed scores, flacc scores, staying time in pacu will be recorded. these data will be evaluated with statistically.

asa i-ii, 3-12 years old children who will operate due to tonsillectomy and adenoidectomy. will be participated in to this study. all participants will divide into the three groups. in groups i, 2,5 mg/kg propofol and 0,5 mg/kg ketamine will apply at anaesthesia induction. general anaesthesia will be performed with 5/1 ratio of ketamine-propofol mixture with %67 of mcfarlan dose regiment. in groups ii, 2,75 mg/kg propofol and 0,41 mg/kg ketamine will apply at anaesthesia induction. general anaesthesia will be performed with 6,7/1 ratio of ketamine-propofol mixture with %80 of mcfarlan dose regiment. in groups iii, 3 mg/kg propofol and 0,3 mg/kg ketamine will apply at anaesthesia induction. general anaesthesia will be performed with 10/1 ratio of ketamine-propofol mixture with %90 of mcfarlan dose regiment. mcfarlan dose regiments include 15 mg/kg/h infusion during 15 minutes, 13 mg/kg/h infusion during second 15 minutes, 11 mg/kg/h infusion from 30 to 60 minutes, 10 mg/kg/h from 1 to 2 h. anaesthesia dept will be detect with bis monitoring during operation. after than surgical operation recovery time, paed scores, flacc scores, staying time in pacu and extubation time will be record. at the end of the study, these data will be evaluated with statistically.

Eligibility criteria:
inclusion criteria: * asa i-ii children * children who will be performed to adenoidectomy and tonsillectomy surgical operations exclusion criteria: * asa iii-iv children * patients over the age of 13
effect of dexamethasone as an adjuvant to bupivacaine in bilateral erector spinae block on postoperative pain and diaphragmatic function after pediatric cardiac surgeries : a randomized controlled clinical trial

Conditions: Pediatric Cardiac Surgery

Summary: the aim of this study is to figure out the efficacy of dexamethasone addition to bupivacaine versus bupivacaine alone in bilateral erector spinae plane block on postoperative analgesia after pediatric cardiac surgeries

the recently introduced ultrasound-guided interfascial plane block, bilateral erector spinae plane block (espb) is a viable option for management of postoperative pain after midline sternotomy. it is expected to provide an analgesic cover spanning the entire thorax at the desired dermatomes including the midline, which could prove beneficial for cardiac surgery through midline sternotomy. indications for espb for postoperative analgesia in pediatric surgeries to date include thoracotomy, video-assisted thoracoscopic surgery, vascular ring repair and sternotomy. dexamethasone is a synthetic glucocorticoid acting as an anti- inflammatory. it inhibits the release of inflammatory mediators such as interleukins and cytokines. several studies have shown that a preoperative dose of dexamethasone added to local anesthetic agents has promising results in reducing postoperative pain and improving the quality of analgesia

Eligibility criteria:
inclusion criteria: * american society of anesthesiologists (asa) physical status i and ii * undergoing cardiac surgical procedures through a midline sternotomypreoperative ejection fraction \<35% exclusion criteria: * low-cardiac-output syndrome * ventricular arrhythmia * preoperative inotropic support * known allergies to any of the study drugs * intubation for more than 3 hours or re-exploration * a redo or emergency surgery * contraindications to regional anesthesia as coagulopathy and infection in site of block.
comparison of two kinds of postoperative analgesia after amputation

Conditions: Pain; Complications

Summary: pain after amputation is a significant problem among amputees. phantom limb pain may appear in up to 85% of patients and is usually resistant to a wide variety of treatments.it is believed that regional anesthesia, by preventing the establishment of central sensitization, may play a role in reducing the incidence of acute and chronic pain. therefore the investigators will compare two methods of postoperative analgesic after after amputation by their efficiency and complication.

peripheral nerve transection results in an afferent nociceptive barrage that initiates spinal cord hyperexcitability with expansion of the receptive fields of dorsal horn neurons that respond to the nearest intact afferents. these neuroplastic changes are believed to be responsible for the development of postsurgical chronic pain syndromes, including phantom limb and stump pain.at present, there are no randomized studies with sample sizes that ensure power, or blinded for end-point assessment,to support the evidence on pharmacological and non-pharmacological treatments of pain after amputation. consequently, our study was designed to arrive at clear conclusions about treatment efficacy and to give stronger recommendations for clinical practice.

Eligibility criteria:
inclusion criteria: 1. patients of american association of anesthetists（asa）grade 1 or 2 2. aged between 18 and 65 years 3. undergoing elective total knee replacement exclusion criteria: 1. mental illness can not match 2. nerve block, epidural anesthesia contraindicated 3. people who have slow-type arrhythmias 4. history of chronic headaches and long-term use of analgesic drugs 5. people who were postoperative consciousness, language or hearing impaired

Keywords: local analgesia system ropivacaine analgesic efficacy after operation postoperative
the role of omnilenz® in the treatment of small corneal perforations secondary to exposure keratitis in icu patients

Conditions: Corneal Perforation; Exposure Keratitis; Infectious Keratitis

Summary: case series of 5 icu patients in farwaniya hospital who developed exposure keratitis and a subsequent small corneal perforation between april 2022 and april 2024. the investigators highlight the non-surgical role of omnilenz® in the treatment of small corneal perforations secondary to exposure keratitis. the inclusion criteria were corneal perforation less than 1mm in size, positive culture \& sensitivity results and showing initial improvement on topical antibiotic eye drops.

the primary outcome measures were healing of the corneal perforation, a negative seidel test and reformation of the anterior chamber. secondary outcome measures were improvement of all three of ciliary injection, state of epithelial defect, and corneal infiltration.

Eligibility criteria:
inclusion/exclusion criteria: * patients with small corneal perforations measuring \ 1mm) were excluded. * patients with conclusive results of keratitis (confirmed via culture and sensitivity scraping) and showing improved keratitis following antibiotic treatment. those with no confirmed keratitis through c\&s or with inconclusive scraping results were excluded. * no age or gender restrictions were applied.